PBAC Public Summary Documents – September 2022
Page last updated: 25 August 2023
Public Summary Documents relating to the September 2022 PBAC meeting.
- Cannabidiol: Oral liquid 100 mg per mL, 100 mL; Epidyolex® – September 2022
- Quadrivalent influenza vaccine (surface antigen, inactivated, cell-based): Injection 15 microgram in 0.5 mL needle-free pre-filled syringe, Injection 15 microgram in 0.5 mL pre-filled syringe with attached needle; Flucelvax® Quad – September 2022
- Ruxolitinib: Tablet 5 mg, Tablet 10 mg; Jakavi® – September 2022
- Tixagevimab and cilgavimab: Pack containing 1 vial of tixagevimab 150 mg in 1.5 mL and 1 vial of cilgavimab 150 mg in 1.5 mL; Evusheld® – September 2022 – December 2022
- Vosoritide: Powder for injection 0.4 mg with diluent, Powder for injection 0.56 mg with diluent, Powder for injection 1.2 mg with diluent; Voxzogo® – September 2022
